Left-sided RAS/BRAF wild-type metastatic colorectal cancer patients with unresectable liver-limited disease at diagnosis may represent a subset of ideal candidates for tailored conversion strategies with the best available benefit–risk ratio, especially those with favorable biological behavior. Here, BRAF is linked to metastatic colorectal cancer.